IL144285A0 - Pharmaceutical compositions containing a vasopeptidase inhibitor - Google Patents

Pharmaceutical compositions containing a vasopeptidase inhibitor

Info

Publication number
IL144285A0
IL144285A0 IL14428500A IL14428500A IL144285A0 IL 144285 A0 IL144285 A0 IL 144285A0 IL 14428500 A IL14428500 A IL 14428500A IL 14428500 A IL14428500 A IL 14428500A IL 144285 A0 IL144285 A0 IL 144285A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
vasopeptidase inhibitor
vasopeptidase
inhibitor
Prior art date
Application number
IL14428500A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL144285A0 publication Critical patent/IL144285A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14428500A 1999-03-29 2000-03-09 Pharmaceutical compositions containing a vasopeptidase inhibitor IL144285A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12694299P 1999-03-29 1999-03-29
PCT/US2000/006091 WO2000057883A1 (en) 1999-03-29 2000-03-09 Use of vasopeptidase inhibitors to treat angina pectoris

Publications (1)

Publication Number Publication Date
IL144285A0 true IL144285A0 (en) 2002-05-23

Family

ID=22427490

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14428500A IL144285A0 (en) 1999-03-29 2000-03-09 Pharmaceutical compositions containing a vasopeptidase inhibitor

Country Status (17)

Country Link
US (1) US6140319A (pt)
EP (1) EP1165088A4 (pt)
JP (1) JP2002540157A (pt)
KR (1) KR20020002487A (pt)
CN (1) CN1347321A (pt)
AU (1) AU768880B2 (pt)
BR (1) BR0009289A (pt)
CA (1) CA2368616A1 (pt)
CZ (1) CZ20013453A3 (pt)
HK (1) HK1039894A1 (pt)
HU (1) HUP0200662A3 (pt)
IL (1) IL144285A0 (pt)
MX (1) MXPA01009654A (pt)
NO (1) NO20014697L (pt)
RU (1) RU2245147C2 (pt)
WO (1) WO2000057883A1 (pt)
ZA (1) ZA200107962B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198839A1 (en) * 2000-08-23 2004-10-07 Dean Herbert M. Cardioprotective dosage units
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2003053353A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Administration of vasopeptidase inhibitors to reduce pulse pressure
WO2008001311A2 (en) * 2006-06-26 2008-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
IL98546A (en) * 1990-06-22 1996-05-14 Fisons Plc History of Aster ECA Inhibitors Preparation and Pharmaceutical Preparations Containing Them
GB9103454D0 (en) * 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5155100A (en) * 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
US5294632A (en) * 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5244889A (en) * 1991-11-26 1993-09-14 Ciba-Geigy Corporation Certain macrocyclic lactam derivatives
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
DE69315808T2 (de) * 1992-11-17 1998-04-09 Smith & Nephew Inc Vorrichtung zur Befestigung von Nahtmaterial
GB9310075D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
EP0706525A1 (en) * 1993-06-30 1996-04-17 Novartis AG Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ace
EP0655461B1 (en) * 1993-11-16 2000-06-07 Novartis AG Cyclic amino acid derivatives having ACE and NEP inhibiting activity
CA2182198A1 (en) * 1994-01-28 1995-08-03 William Byrne A pharmaceutical product comprising a salicylate of an esterifiable ace-inhibitor
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
FR2729668A1 (fr) * 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5744781A (en) * 1995-08-07 1998-04-28 General Electric Company Method and apparatus for laser shock peening
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination

Also Published As

Publication number Publication date
CN1347321A (zh) 2002-05-01
EP1165088A1 (en) 2002-01-02
JP2002540157A (ja) 2002-11-26
BR0009289A (pt) 2002-01-22
WO2000057883A1 (en) 2000-10-05
KR20020002487A (ko) 2002-01-09
HK1039894A1 (zh) 2002-05-17
ZA200107962B (en) 2003-01-02
US6140319A (en) 2000-10-31
AU3732100A (en) 2000-10-16
AU768880B2 (en) 2004-01-08
EP1165088A4 (en) 2002-09-04
MXPA01009654A (es) 2002-05-14
NO20014697D0 (no) 2001-09-27
HUP0200662A2 (hu) 2002-07-29
HUP0200662A3 (en) 2004-07-28
RU2245147C2 (ru) 2005-01-27
CZ20013453A3 (cs) 2002-02-13
NO20014697L (no) 2001-09-27
CA2368616A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
IL147970A0 (en) Pharmaceutical compositions containing tripeptides
IL187526A0 (en) Pharmaceutical compositions containing an a?? fragment
IL148357A0 (en) Pharmaceutical compositions containing a benzamide derivative
IL145177A0 (en) A pharmaceutical composition containing xenon
IL149138A0 (en) Pharmaceutical compositions containing metformin
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
HUP0300544A3 (en) Pharmaceutical compositions containing integrin expression inhibitors
IL148630A0 (en) Compounds and pharmaceutical compositions for inhibiting cathepsin s
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
GB0019028D0 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
HK1044476A1 (en) Medicinal compositions
GB0009584D0 (en) Pharmaceutical compositions
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
GB9923436D0 (en) Pharmaceutical compositions
EP1166786A4 (en) MEDICAL COMPOSITIONS
GB9927315D0 (en) Inhibitor compositions
AU8576801A (en) Pharmaceutical compositions
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
GB9904163D0 (en) Pharmaceutical compositions
HUP0200747A2 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions